Trials / Terminated
TerminatedNCT03511222
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that vorolanib in combination with checkpoint inhibitors (pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for hepatocellular carcinoma (HCC)) may improve immunotherapy efficacy by overcoming treatment resistance of checkpoint inhibitors in gastrointestinal (GI) cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vorolanib | Patients should take vorolanib at approximately the same time every day with food. |
| DRUG | Nivolumab | Standard of care |
| DRUG | Pembrolizumab | Standard of care |
Timeline
- Start date
- 2018-09-11
- Primary completion
- 2019-08-15
- Completion
- 2020-05-28
- First posted
- 2018-04-27
- Last updated
- 2020-07-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03511222. Inclusion in this directory is not an endorsement.